Securecell, a Zurich based biotech company that automates and manages bioprocess workflows, enabling biopharma innovator to bring new therapies in a safe, efficient and economical way to the patient. Securecell’s product portfolio consists of a comprehensive Process Information Management System (Lucullus), which is also the company's flagship product and an automated sampling and sample processing instrument (Numera).
The company has recently expanded its market activities in Asia and Israel by cooperating with Alit Life Science, Biofors Global and Danyel Biotech To build Securecell's market presence in China, Korea and Israel. The partners will initially focus on distributing Lucullus PIMS software solution as well as Numera auto sampling and sample processing machine. In a second step, they will enrich their portfolio by adding Securecell’s new products tailored to improving perfusion cultures at the benchtop scale.
“Alit, Biofors and Danyel were selected based on the strong connection and network within China, Korea and Israel biopharma market as well as the existing competence in selling high-value products to bioprocessing industries. It is an excellent addition to our expanding worldwide network of marketing and sales partners addressing the needs of a growing and demanding biopharma business”, said Michele Bomio, CFO of Securecell.
“We are very excited to cooperate with Securecell in China. I believe there is a big market for their advanced products, both the software system and the automation sampling machine. This new cooperation will help Chinese customers to use innovative and world-leading software engineering technology to improve their processes in R&D and production, thanks also to Securecell’s process analytical technology (PAT) system, which helps to supply better biotech medicaments to help the improvement of human health", said David Chen, founder of Alit Life Science.
Luly Gurevich, CEO of Danyel Biotech, said: “This new partnership with Securecell helps us to deliver high-end technological solutions in the biopharmaceutical industry and biological research fields. Lucullus will enable much better control of our customers' processes and having Numera will open new opportunities, along with our wide portfolio of instrumentation, media, supplements and consumables for Upstream.”